Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5275 USD | -3.19% | -7.31% | +2.87% |
Financials (USD)
Sales 2024 * | 111M | Sales 2025 * | 71.47M | Capitalization | 63.52M |
---|---|---|---|---|---|
Net income 2024 * | -89M | Net income 2025 * | -119M | EV / Sales 2024 * | 0.4 x |
Net cash position 2024 * | 19.23M | Net cash position 2025 * | 88.14M | EV / Sales 2025 * | -0.34 x |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-0.61
x | Employees | 173 |
Yield 2024 * |
379% | Yield 2025 * |
379% | Free-Float | 90.7% |
Latest transcript on Atara Biotherapeutics, Inc.
1 day | -3.19% | ||
1 week | -7.31% | ||
Current month | -5.95% | ||
1 month | -5.19% | ||
3 months | -20.91% | ||
6 months | -22.20% | ||
Current year | +2.87% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | 49 | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
Matthew Fust
BRD | Director/Board Member | 59 | 14-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 415 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-13 | 0.5275 | -3.19% | 562,584 |
24-06-12 | 0.5449 | -3.06% | 454,505 |
24-06-11 | 0.5621 | +7.68% | 656,863 |
24-06-10 | 0.522 | -1.29% | 1,203,628 |
24-06-07 | 0.5288 | -7.08% | 1,321,147 |
Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.87% | 63.52M | |
+17.73% | 124B | |
+16.88% | 111B | |
-9.04% | 23.17B | |
+4.40% | 22.94B | |
-38.15% | 17.42B | |
-7.75% | 17.42B | |
-15.36% | 16.9B | |
+3.42% | 13.71B | |
+29.63% | 11.82B |
- Stock Market
- Equities
- ATRA Stock